Latest DCIS Stories
In a significant advance for patients with ductal carcinoma in situ, researchers have developed and prospectively validated a multigene test to identify the risk for recurrence of breast cancer.
REDWOOD CITY, Calif., May 24, 2011 /PRNewswire/ -- Genomic Health, Inc.
Combining Radiation and Tamoxifen Therapy to Lumpectomy for DCIS Reduces Risk of Cancer Recurrence PITTSBURGH, March 14, 2011 /PRNewswire-USNewswire/ -- Adding radiation and/or tamoxifen therapy to the treatment plan of women who undergo a lumpectomy for ductal carcinoma in situ (DCIS), the most common form of non-invasive breast cancer, reduces the risk of a dangerous cancer recurrence, according to a study published today in the Journal of the National Cancer Institute by physicians at...
Women with ductal carcinoma in situâ€”DCISâ€”who later develop invasive breast cancer in the same breast are at higher risk of dying from breast cancer than those who do not develop invasive disease.
Non-invasive breast cancer, or ductal carcinoma in situ (DCIS), is commonly treated with either breast-conserving surgery (with or without follow-up radiation) or mastectomy.
Ductal carcinoma in situ (DCIS), or non-invasive breast cancer, is typically treated with either breast-conserving surgeryâ€”with or without follow-up radiationâ€”or mastectomy.
In a new UCSF study of more than 2 million mammogram screenings performed on nearly 700,000 women in the United States, scientists for the first time show a direct link between reduced hormone therapy and declines in ductal carcinoma in situ (DCIS) as well as invasive breast cancer.
NORTHFIELD, Ill., July 29 /PRNewswire-USNewswire/ -- Recent media reports of potential misdiagnosis of early-stage breast cancer may frighten women away from breast cancer screening that could save their lives.
- Growing in low tufty patches.